ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset

Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck squamous cell carcinoma (HNSCC), including a first look at overall survival (OS) data for HPV-negative patients as the biotech enrolls for a pivotal trial in the indication.